

February 6, 2026
Mochida Pharmaceutical Co., Ltd.

Announcement of the Establishment of Mochida Medical USA, Inc.

Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Naoyuki Mochida; hereinafter "Mochida Pharmaceutical") hereby announces the establishment of Mochida Medical USA, Inc. in the United States.

Company Overview

(1) Name	Mochida Medical USA, Inc.
(2) Location	Located near Memphis, Tennessee, USA
(3) Job title and name of representative	President: Fumihiko Mori
(4) Description of business	Sales and development of medical devices
(5) Share capital	USD 1.41 million
(6) Date of establishment	July 28, 2025
(7) Major shareholders and ownership ratio	Mochida Pharmaceutical 100 %

Mochida Pharmaceutical is engaged in the biomaterials business that involves projects based on alginate, which has numerous potential applications in the medical and biotechnological field. As part of the global expansion of the biomaterials business, Mochida Pharmaceutical has established Mochida Medical USA, Inc. as a base for its U.S. operations. Mochida Medical USA, Inc. is expected to focus on activities including the sales of ReFeel, a material that supports nerve regeneration, and the development of new medical devices in the U.S.

Through these activities in the U.S., Mochida Pharmaceutical will strive to contribute to improving patients' quality of life.

Contact:

Mochida Pharmaceutical Co., Ltd.
Public Relations, Corporate Planning Department
Mail: webmaster@mochida.co.jp

###

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.